Why the study?
Does adjunctive CsA treatment compared to sequential RPM treatment inhibit monocyte/macrophage associated cytokines/chemokines in RPM-pretreated cardiac graft recipient rats?
Does adjunctive CsA treatment compared to sequential RPM treatment inhibit monocyte/macrophage associated cytokines/chemokines in RPM-pretreated cardiac graft recipient rats?
In a rat cardiac allograft model, adjunctive CsA is more effective than sequential Rapamycin alone in restraining inflammatory chemokine mRNA expression, though both induce TGF-beta hyperexpression.
Answers are grounded in this paper and cite their sources.
Adjunctive CsA may more potently suppress select chemokines than RPM in rat allografts; hypothesis-generating and requires clinical validation before any practice change.
BACKGROUND: Although treatment of LEW rats with Rapamycin (RPM) prolongs the survival of LBNF1 cardiac allografts to ca. 50 days, it fails to prevent late activation of macrophage/monocyte-associated chemokines. METHODS: A 7-day course with RPM or CsA was introduced at 1-week posttransplant in RPM-pretreated hosts. At day 35, intragraft mRNA expression of IL-2, IFN-gamma, TGF-beta, IL-12 (p40), MCP-1, and RANTES was evaluated. RESULTS: RPM as a sequential treatment markedly inhibited mRNA levels coding for IL-2/IFN-gamma, and MCP-1. However, RPM monotherapy failed to prevent the expression of IL-12 (p40) and RANTES. Adjunctive treatment with CsA markedly depressed IL-12 (p40) and RANTES, and to a lesser extent MCP-1 mRNA, as compared with RPM-treated groups. Significant increase of TGF-beta mRNA expression was revealed after sequential RPM and adjunctive CsA treatment. CONCLUSIONS: A combination of RPM and CsA is more effective in restraining mRNA expression than RPM alone; however, either therapy is associated with TGF-beta hyperexpression.
No takes yet. Share an insight, caveat, or question.
Wa̧sowska et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: